Nonalcoholic Steatohepatitis (NASH) Research
Nonalcoholic steatohepatitis (NASH) is fast becoming the leading cause of liver failure today. As the worldwide prevalence of obesity and type 2 diabetes (T2D) increases, so do the complications of NASH.
We are a leading, global contract research organization. Our team of more than 4,300 employees working across 47 countries delivers collaborative clinical development services and solutions Designed Around You®.
From study design through product launch and beyond, Chiltern is the only resource you need. Our development teams have conducted thousands of clinical trials for a wide range of drugs, biologics, medical devices and diagnostics across all phases of development, involving different study populations and across many therapeutic areas.
Nonalcoholic steatohepatitis (NASH) is fast becoming the leading cause of liver failure today. As the worldwide prevalence of obesity and type 2 diabetes (T2D) increases, so do the complications of NASH.